Company intelligence / Profile preview
Seelos Therapeutics, Inc.
New York, New York, United Statesseelostherapeutics.com ↗
- Ownership
- Public · SEEL
- Development stage
- Other
01
Overview
Seelos Therapeutics develops therapies for CNS disorders and rare diseases. Its lead asset, SLS‑002 intranasal racemic ketamine for ASIB in MDD, has completed Phase II studies. Other pipeline assets include trehalose IV infusion for ALS/SCA/Huntington's/Alzheimer's disease at Phase IIb or earlier stages; gene therapies and peptide inhibitors targeting Parkinson's disease are preclinical to early clinical stage. The company faces financial challenges after being delisted from Nasdaq but remains active with ongoing development efforts.[7]
- Therapeutic areas
- Rare DiseasesPsychiatryNeurology
- Modalities
- Small molecules[9]Gene therapy[3][9]Peptide inhibitors[3][6][9]PROTACs[9]AAV-based gene therapy[9]
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Not specifically disclosed; company notes ongoing discussions about potential partnerships focused on mental health initiatives.[10]
Beyond the preview
Go deeper on Seelos Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seelos Therapeutics, Inc..